|Day Low/High||33.97 / 34.22|
|52 Wk Low/High||29.83 / 37.39|
The main headwind for Regeneron is that Swiss pharma giant Novartis could soon be a rival to the eye drug that drives most of Regeneron's revenue.
The board of directors of Pfizer Inc. today declared a 32-cent third-quarter 2017 dividend on the company's common stock, payable September 1, 2017, to shareholders of record at the close of business on August 4, 2017.
Morgan Stanley analyst David Risinger argued for the drugmaker to part ways with its consumer health division.
The main thrust of the order appears to be easing regulatory hurdles to drug approvals, which could lower the cost of bringing new treatments to market and thus lower prices.
Shares of Pfizer are moving well again Tuesday as the stock gains momentum following Monday's trendline break.
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.
Pfizer Inc. (NYSE:PFE) today announced that it has started a Phase 1 trial in healthy volunteers of PF-06760805, an investigational vaccine designed to help protect against Group B Streptococcus (GBS) infection.
Pfizer Inc. (NYSE:PFE) announced today detailed results from ORAL Strategy, a head-to-head, noninferiority Phase 3b/4 study of XELJANZ ® (tofacitinib citrate) 5 mg twice daily (BID) as monotherapy or in combination...
Pfizer Inc. (NYSE: PFE)and Basilea Pharmaceutica Ltd.
The FDA approval comes amidst America's struggle with an opioid epidemic.
Generic drugmakers are likely to limit themselves to acquisitions of small- and mid-sized companies in the immediate future because of over-leveraging and turmoil in the executive ranks..
Pfizer Inc. (NYSE:PFE), in partnership with Parents magazine (NYSE:MDP), announced today the results of a national survey of more than 2,000 new and expectant parents assessing their knowledge of childhood infectious...
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced that the U.
Merck (NYSE:MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc.
Prostate cancer drug sales have dropped during a federal investigation of charities that support the industry.
- Amendment accelerates anticipated PROSPER top-line results by two years -
Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Pfizer Inc.
This tactic for PFE is a rare setup for those bullish in any underlying stock.
The day before Amgen appeared in court, the biopharma giant announced a submission to change its label on powerhouse drug Repatha.
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, President, Worldwide Research and Development, at the Goldman Sachs 38 th Annual Global Healthcare...
Companies also Announce Phase 1/2 Clinical Trial Evaluating SB-525 in Adults with Severe Hemophilia A is Now Open for Enrollment
The handwringers will be out in full force. Their fear creates buying opportunities.
The companies are competing for approval for drugs that treat prostate cancer, the second most common cancer in men.
Pfizer Inc. (NYSE:PFE) announced today that the U.
Why study charts? Because charts are like the footprints at the scene of the crime, clues to what the big money managers are likely thinking, Jim Cramer says.